Advancements in AI-driven diagnostics could transform cardiology, enabling autonomous interpretation of up to 80% of cardiac imaging within a decade. David Ouyang, MD, discusses overcoming barriers to running…
NEW YORK (Reuters Health) – Using a distal filter to protect against emboli during coronary stent implantation increases long-term rates of stent thrombosis and target vessel revascularization, investigators…
NEW YORK (Reuters Health) – Percutaneous extraction of pacemaker or implantable cardioverter-defibrillator (ICD) leads is safe in patients with cardiac vegetations, investigators report. And as long as blood…
Richard J Shemin, MD, Chief of Cardiothoracic Surgery, UCLA David Geffen School of Medicine, discusses hybrid approaches to cardiology and cardiothoracic surgery, such as operation rooms where interventional…
NEW YORK (Reuters Health) – Asymptomatic patients with a low ankle brachial index don’t seem to get cardiovascular protection from aspirin, randomized trial results suggest. The subjects came…
NEW YORK (Reuters Health) – Baseline platelet function is only modestly related to ischemic outcomes after percutaneous coronary intervention (PCI) in low-risk patients, according to a study in…
NEW YORK (Reuters Health) – Beta blockade before computed tomographic coronary angiography (CTA) can improve image quality, but a substantial number of patients who require CTA have contraindications…
NEW YORK (Reuters Health) – An implantable cardioverter-defibrillator (ICD) should be considered when patients with long QT syndrome (LQTS) have syncope while on beta-blockers. That’s according to authors…
Richard J Shemin, MD, Chief of Cardiothoracic Surgery, UCLA David Geffen School of Medicine, discusses anticoagulation protocol for patients following mitral valve repair, and also the Maze procedure…
Joshua Grill, PhD, Director, Katherine and Benjamin Kagan Alzheimer’s Disease Treatment Development Program, UCLA, Alzheimer’s Disease, which is currently a worldwide healthcare crisis and it is expected to…
NEW YORK (Reuters Health) – Researchers cut short a clinical trial of the endothelin blocker avosentan in patients with diabetic nephropathy because it was linked with fluid overload…
